Friday, September 29, 2023


Biotechnology News Magazine

SciTech Development Announces the Launch of Equity Crowdfunding Campaign

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

SciTech Development LLC, a specialty pharmaceutical company, has announced the launch of its equity crowdfunding campaign on StartEngine.

SciTech Development plans to grow the company, scale-up clinical drug manufacturing, and to commence the company’s first clinical trial of ST-001 nanoFenretinide for the treatment of non-Hodgkin’s lymphoma. Non-Hodgkin’s lymphomas are cancers that begin in the lymphatic system, which is part of the body’s germ-fighting immune system.

SciTech Development notes their patented lead drug candidate ST-001 nanoFenretinide is a combination of the company’s proprietary drug delivery platform known as SDP, and fenretinide, a drug with a well-documented safety profile. We are also pleased to announce that ST-001 has an FDA approved Investigational New Drug Application (IND) and Orphan Drug Designation (ODD) for two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). ST-001 is ready to enter the clinic at Rush University Medical Center (RUMC) in Chicago, IL where it has IRB approval (Institutional Review Board).

Earle Holsapple, President of SciTech Development relays that FDA approval of ST-001 would be a significant step towards revenue generation, but more importantly, believes that SciTech’s scientific breakthroughs will have a profound impact on patients who are battling cancer.

Visit to invest in SciTech’s crowdfunding campaign, early investors qualify for time-based bonuses. For company, product, and investor information visit Detailed information regarding SciTech’s science and the company can be found at

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine